Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect
- Trial Design
- Efficacy
- Safety
This morning, Definium Therapeutics announced positive topline results from its Phase 3 study of LSD (DT120) for major depressive disorder (MDD).
It’s the first Phase 3 data for LSD, and for Definium.
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In